Amgen launches late-stage obesity trial in patients who switch from rival drugs

Amgen is launching three new late-stage trials for its long-acting obesity shot MariTide, including one designed to test the drug in patients switching away from Eli Lilly and Novo Nordisk's blockbuster GLP-1s. Patients in the ...